Clinical Trial Update: CPX-351 in Higher Risk Myelodysplastic Syndromes [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial updates for CPX-351 in higher-risk myelodysplastic syndromes have been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• CPX-351 (liposomal daunorubicin/cytarabine)

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: COMPLETED